Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2022

View Archived Issues

Novel cdkl5-mutated zebrafish model of CDKL5 deficiency disorder

Insulin is tissue-specific, with link to weight complex

Purdue Research Foundation patents protein kinase inhibitors

Universite de Franche-Comte presents compounds targeting histamine H3 receptors

TCR-modified T cells targeting TdT show antileukemia promise in vivo

SCN5A tied to drug-induced cardiac arrythmia

PEGylated circularly permuted capsule depolymerase enzyme protects mice from anthrax infection

VelociT mouse model for analyzing T-cell function in human disease

Ono and Neurimmune expand drug discovery collaboration for neurodegenerative diseases

EZH2 as a promising therapeutic target for prostate cancer

MCC-1381, a pan-HDAC inhibitor with promising anticancer activity

ZIP8 found to correlate with severe rheumatoid arthritis

4basebio and eTheRNA collaborate to evaluate linear DNA for mRNA production

Avacta selects FAP-targeted proteasome inhibitor for preclinical development

SUW-133 diminishes HIV viral load in vivo

Researchers suggest ZEB2 targeting as an approach for atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...